mercredi 28 novembre 2018

Onco Actu du 28 novembre 2018

1.4 Biologie - Technos

Largest study of CRISPR-Cas9 mutations creates prediction tool for gene editing [Sanger Institute]

Born CRISPRed. Now What? [In the Pipeline]

Amid uproar, Chinese scientist defends creating gene-edited babies [STAT]

How the genome-edited babies revelation will affect research [Nature]

4.12 Biopsies liquides

Nanoscale blood test technique set to springboard cancer discoveries [Cancer Research UK]

Johns Hopkins Researchers Advance Role of Circulating Tumor DNA to Detect Early Melanoma Growth, Uncover Treatment Options [Johns Hopkins]

4.7 Dép., diag. & prono. - Col de l'utérus

Cervical cancer screening rate falls to lowest for at least 21 years [The Telegraph]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

First children set to receive Novartis’ Kymriah [PharmaTimes]

5.12.3 Immunothérapies-combinaisons

BMS' second small-cell trial flop endangers Opdivo lung cancer approval: analyst [FiercePharma]

Bristol-Myers' Opdivo falls short again in small cell lung cancer [BiopharmaDive]

5.2 Pharma

Halozyme drops PFS co-primary endpoint from PEGPH20 phase 3 [FierceBiotech]

Halozyme Announces Change In Primary Endpoint For HALO-301 To Overall Survival [Halozyme]

5.2.1 Pharma - Partenariats

BeiGene bags Asian rights to Zymeworks’ HER2 bispecifics [FierceBiotech]

5.3.4 Traitements - AMM (FDA, EMA,...)

European approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer [Pharmafile]

European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell Lung Cancer in Patients Previously Treated with Crizotinib, Advancing Treatment Paradigm in Europe [Takeda]

5.4 Traitements - Economie

'Tissue agnostic' cancer drug from Bayer, Loxo comes with high price, money-back guarantee [FiercePharma]

Loxo cancer drug wins US approval in advance for targeted therapy [BiopharmaDive]

First Targeted Cancer Drug Approved Based on Mutation Rather than Tumor Type [Memorial Sloan Kettering Cancer Center]

6.1 Observation

Unfinished business - An assessment of the national approach to improving cancer services in England 1995–2015 [The Health Foundation]

Cancer survival in England still lagging behind other countries [Cancer Research UK]

10% of bowel cancer patients can wait more than a year to start treatment [Cancer Research UK]

6.10.1 Politiques (USA)

Cancer Pushes New York’s ‘First Girlfriend,’ Sandra Lee, Onto Political Stage [NY Times]

6.6 Publications

Funders flesh out details of Europe’s bold open-access plan [Nature]

Biomedical research is becoming more open about its funding and data [Nature]

6.9 Controverses

Should Evidence-Based Medicine Be Replaced by Interpersonal Medicine? [Science-Based Medicine]